Online citations, reference lists, and bibliographies.

Long‐term Survival In Advanced Ovarian Carcinoma Following Cytoreductive Surgery With Standard Peritonectomy Procedures

A. Tentes, C. Mirelis, S. Markakidis, K. Bekiaridou, I. Bougioukas, A. Xanthoulis, E. Tsalkidou, G. Zafiropoulos, I. Nikas
Published 2006 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
The impact of cytoreductive surgery with standard peritonectomy procedures has not been extensively assessed in the treatment of advanced ovarian cancer. The aims of the study are to report the long-term results of patients with advanced ovarian cancer undergoing cytoreductive surgery with standard peritonectomy procedures and to identify the prognostic indicators that may affect outcome. The records of 74 women with advanced ovarian cancer were retrospectively reviewed. Clinical indicators were correlated to survival. The hospital mortality and morbidity rates were 13.5% and 28.4%, respectively. Complete or near-complete cytoreduction was possible in 78.4% of the patients. Overall 10-year survival rate was 52.5%. Complete cytoreductive surgery, small-volume tumor, low-grade tumor, the absence of distant metastases, the use of systemic adjuvant chemotherapy, performance status >70%, and limited extent of peritoneal carcinomatosis were favorable indicators of survival. Complete cytoreduction (P= 0.000) and treatment with systemic chemotherapy (P= 0.001) independently influenced survival. Recurrence was recorded in 37.8% of the patients and was independently influenced by the tumor grade (P= 0.037). Cytoreductive surgery with standard peritonectomy procedures followed by adjuvant chemotherapy offers long-term survival in women with advanced ovarian cancer who have limited peritoneal carcinomatosis and no distant and irresectable metastases.
This paper references
10.1002/jso.10270
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.
Konstantinos M. Stamou (2003)
Peritoneal mesothelioma proposing for a staging system
G Sebbag (2001)
10.1097/00000658-199501000-00004
Peritonectomy Procedures
Paul H Sugarbaker (2003)
10.1186/1477-7819-2-21
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
Pompiliu Piso (2004)
Secondary cytoreductive surgery for ovarian cancer.
T. Burke (1994)
10.1053/ejso.2002.1380
Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
Antonios-Apostolos K Tentes (2003)
10.1177/107327489600300205
Cytoreductive Surgery in Ovarian Cancer: Why, When, and How?
Roberts (1996)
10.1006/gyno.1999.5397
Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival.
F. Parazzini (1999)
10.1111/j.1525-1438.2003.13319.x
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1245/ASO.2004.03.085
Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease
Dominique Elias (2004)
10.1007/978-1-4613-1247-5_23
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
Pierre Jacquet (1996)
Ovarian cancer: rethinking prognostic factors and chemotherapy
J. Neijt (1994)
10.1053/ejso.2001.1152
Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
G. Begossi (2002)
Advances in the management of epithelial ovarian cancer.
Sanaz Memarzadeh (2001)
10.1016/j.ygyno.2004.03.006
Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
S. Isonishi (2004)
10.1102/1470-7330.2007.0030
Cytoreductive surgery in ovarian cancer
Christophe Pomel (2007)
10.1007/978-1-4613-1247-5_6
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
P. Sugarbaker (1996)
A mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with the Coliseum technique
A Stephens (2000)
10.1016/j.ygyno.2004.01.029
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
D. Chi (2004)
10.1186/1477-7800-2-3
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
Rhonda L Harmon (2005)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1016/j.suronc.2004.08.010
Poorer survival of elderly patients with ovarian cancer: a population-based study.
P. Petignat (2004)
10.1111/j.1048-891x.2004.014301.x
Predictive factors for irresectability in advanced ovarian cancer
H. Martínez-Said (2004)
10.1016/S0889-8588(18)30309-5
Prognostic factors in ovarian cancer.
M. Friedlander (1991)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar